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Abstract
Introduction: Post-operative pancreatic fistula (POPF) is a common complication after partial pancre-
atic resection, and is associated with increased rates of sepsis, mortality and costs. The role of fibrin
sealants in decreasing the risk of POPF remains debatable. The aim of this study was to evaluate the
literature regarding the effectiveness of fibrin sealants in pancreatic surgery.
Methods: A comprehensive database search was conducted. Only randomized controlled trials com-
paring fibrin sealants with standard care were included. A meta-analysis regarding POPF, intra-abdominal
collections, post-operative haemorrhage, pancreatitis and wound infections was performed according to
the recommendations of the Cochrane collaboration.
Results: Seven studies were included, accounting for 897 patients. Compared with controls, patients
receiving fibrin sealants had a pooled odds ratio (OR) of developing a POPF of 0.83 [95% confidence
interval (CI): 0.6–1.14], P = 0.245. There was a trend towards a reduction in post-operative haemorrhage
(OR = 0.43 (95%CI: 0.18–1.0), P = 0.05) and intra-abdominal collections (OR = 0.52 (95%CI: 0.25–1.06),
P = 0.073) in those patients receiving fibrin sealants. No difference was observed in terms of mortality,
wound infections, re-interventions or hospital stay.
Conclusion: On the basis of these results, fibrin sealants cannot be recommended for routine clinical
use in the setting of pancreatic resection.
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Introduction
Pancreatic resection represents a major surgical procedure, and
although peri-operative mortality has been reduced to below 5% in
most centres,post-operative morbidity remains high,with 30–60%
of patients experiencing complications.1,2 Post-operative pancre-
atic fistula (POPF) is a commonly feared complication for hepato-
pancreatico-biliary surgeons, owing to its association with
increased mortality, sepsis, hospital stay and costs.3 The incidence
of POPF after pancreatico-duodenectomy (PD) varies in different
series, lying between 5% and 35%.4,5 The POPF rate after left
pancreatectomy (LP) ranges from 13% to 64%.6
Several strategies have been proposed in order to prevent POPF
formation, including peri-operative administration of somatosta-
tin analogues,4,5 pancreaticogastrostomy instead of pancreaticoje-
junostomy7 and hand-sutured versus stapler closure of the
pancreatic remnant after LP.6 Fibrin sealants are a group of thera-
peutic agents with several indications, such as helping to achieve
improved local haemostatic control, reinforcing suture lines and
stimulating wound healing.8 Although there are several commer-
cialized formulae, with variations in their precise composition,
fibrin sealants all share the common feature of combining fibrino-
gen and thrombin, in order to mimic the final step of physiologi-
cal haemostasis.8 The effectiveness of fibrin sealants has been
evaluated in several surgical settings, including liver,9,10 hernia,11
orthopaedic,12 urological,13 cardiac14 and breast surgery,15 with
conflicting results.
In the setting of pancreatic resection, there are a number of
previous retrospective and non-randomized studies that have
assessed the role of fibrin sealants in decreasing the POPF rate.16–19
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However, considering the high cost of fibrin sealants, there is a
need for quality evidence regarding their use in daily clinical prac-
tice. To clarify this issue, it was decided to conduct a systematic
review and meta-analysis of randomized controlled trials (RCTs)
evaluating the effect of fibrin sealants on the incidence of POPF
and other complications for patients undergoing pancreatic
surgery.
Methods
Search strategy and inclusion criteria
The present methodology is in accordance with the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA).20
MEDLINE, EMBASE, and the Cochrane Register of clinical
trials (CENTER) were searched from 1966 onwards. The follow-
ing search terms were combined in MEDLINE: ((fibrin seal[M-
eSH Terms]) OR (fibrin sealant[MeSH Terms]) OR (fibrin sealant
system[MeSH Terms]) OR (adhesive, fibrin tissue[MeSH Terms])
OR (fibrin sealant, human[MeSH Terms]) OR (human fibrin seal-
ant[MeSH Terms]) OR (fibrin glue[MeSH Terms]) OR (tissucol-
[MeSH Terms]) OR (tisseel[MeSH Terms]) OR (tachosil) OR
(vitagel) OR (beriplast) OR (biocol) OR (biostat) OR (tachoc-
omb) OR (quixil) OR (evicel) OR (fibrin glue sealing) OR (artiss)
AND ((pancreaticoduodenectomy[MeSH Terms]) OR (pancrea-
ticojejunostomy[MeSH Terms]) OR (pancreaticoduodenecto-
mies[MeSH Terms]) OR (pancreaticojejunostomies[MeSH
Terms]) OR (pancreatic duct[MeSH Terms]) OR (anastomotic
leak[MeSH Terms]) OR (leak, anastomotic[MeSH Terms]) OR
(leakage, anastomotic[MeSH Terms]) OR (pancreatic fistu-
la[MeSH Terms]) OR (pancreatic fistulas[MeSH Terms]) OR
(fistula) OR (fistulae) OR (postoperative complications[MeSH
Terms]) OR (pancreatic remnant) OR (pancreatic stump) OR
(pancreatic surgery) OR (pancreas surgery)). An equivalent query
was formulated in EMBASE and CENTER.
Inclusion criteria were: RCTs comparing the application fibrin
sealants with placebo (or no drug) for adult patients undergoing
pancreatic resection. Patients treated with both PD and LP were
included. There was no inclusion limit regarding the various com-
mercially available fibrin sealant preparation, date of publication,
language or publication status.
Data collection
Two authors extracted data, and disagreements were resolved by
reaching a consensus with the remaining authors. Demographic
and clinical variables of interest were as follows: age, gender, indi-
cation for pancreatic resection and type of surgical procedure. The
fibrin sealant preparation price was systematically collected (as
reported in the included studies or according to the manufacturer
product information). The primary outcome was overall inci-
dence of POPF. The severity of the POPF was graded according to
the International Study Group on Pancreatic Fistula (ISGPF) defi-
nition.21 Secondary outcomes included the impact of the POPF on
the post-operative course (according to the ISGPF grading
system), overall complications (including POPF), sepsis, delayed
gastric emptying, post-operative haemorrhage (digestive or intra-
abdominal), acute pancreatitis, intra-abdominal collections
(infected or not) as diagnosed by a computed tomography scan,
wound infection, necessary invasive procedures (reoperation or
interventional radiology), 30-day mortality and mean length of
hospital stay. The included studies were critically appraised evalu-
ating the quality of reporting of important methodological com-
ponents. The Jadad score,22 which ranks the quality of RCTs on a
five-points scale according to randomization, blinding and attri-
tion, was also used.
Statistical analysis
When the included trials were deemed comparable, their results
were pooled in several meta-analyses. Binary outcomes were com-
bined as pooled odds ratio (OR), and for continuous outcomes,
the weighted mean difference (WMD) was calculated. Ninety-five
per cent confidence intervals (95% CI) were reported. The
number needed to treat (NNT) was calculated as the inverse of the
difference between the control and intervention group event rate.
In studies which reported the median only, the median was either
pooled in the meta-analysis assuming normal distribution or con-
verted to the mean according to previously detailed methodol-
ogy.23 Statistical heterogeneity was assessed using the Q-test with a
significance level set at P = 0.05. To quantify heterogeneity, the I2
measure was used. Data were pooled applying either the fixed
(inverse variance) or random effect model.24 In case of heteroge-
neity or marked clinical variability, it was planned to perform
sensitivity analyses. Separate analyses of populations undergoing
PD or LP were performed. Looking for a consistent POPF defini-
tion, a sensitivity analysis was undertaken retaining only those
trials using the ISGPF definition.21 Lastly, because surgical tech-
nique and the skills of the surgeon are considered to have an
impact on the risk of POPF,25 separate analyses for different sur-
gical techniques (pancreaticojejunostomy or pancreaticogastros-
tomy, hand-sewn or stapled closure of the pancreatic stump in LP)
were carried out. A funnel plot was used to assess publication bias,
as explained in the illustration. All statistical analyses were per-
formed using Stata 12®, Stata Corp., College Station, Texas, USA.
Statistical significance was set at the P < 0.05 level.
Results
Literature search and characteristics of the
included studies
The literature search identified 1415 articles. Hand searching the
reference list of retrieved articles and congress attendance allowed
identification of seven additional trials. Two studies were identi-
fied before publication.26,27 A majority of articles were excluded
because of irrelevant subject based on abstract reading. Twenty-
nine studies were scrutinized. Twenty non-randomized controlled
studies were further excluded, as well as two RCTs: one because
the intervention groups were not suitable for inclusion (pancrea-
ticojejunostomy versus no anastomosis and pancreatic duct occlu-
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sion),28 and another because its methodology was severely flawed
(part of the data were collected retrospectively).29 Seven RCTs
fulfilling the inclusion criteria were retained.26,27,30–34 The PRISMA
flow diagram of the inclusion–exclusion process is depicted in
Fig. 1. Publication dates ranged from 199431 to 2012.26,27,30 Two
trials were held in the United States30,32 and Italy,27,31 and one,
respectively, in Australia,26 Japan34 and France.33 Overall, 897
patients were included (461 in the fibrin sealant group and 436 in
the control group). Three trials included patients undergoing LP
only,27,30,34 two focused on PD26,32 and the remaining two studies
included patients regardless of the site of pancreatic resection.31,33
Table 1 summarizes the characteristics of the included trials.
Critical appraisal
The reporting of important methodological components is sum-
marized in Fig. 2. According to the Jadad score, two30,33 trials were
of high methodological quality. The other five trials were of inter-
mediate (Jadad score = 3),32 and moderate to low (Jadad score
2)26,27,31,34 quality. When considering other sources of bias, the
study by Suc et al.33 had noticeable baseline imbalances between
study groups, as there were significantly more patients in the
fibrin sealant group receiving somatostatin analogue prophylaxis
and more pancreatic parenchyma described as non-fibrous in the
control group. Two studies included only patients with a high-risk
(soft) pancreatic parenchyma.30,32 Of note, Carter et al. excluded
eight (7%) patients with a hard parenchyma after randomiza-
tion.30 There were more men in the fibrin sealant group in one
study.27 Two studies were prematurely interrupted before reaching
the a priori determined sample size, and although the reason for
trial interruption was clearly stated (futility of detecting a differ-
ence following interim statistical analysis), these trials were at a
higher risk of a type II statistical error.30,32 Regarding between-
study comparability, three trials were published after 2005 and
used the ISGPF fistula definition.26,27,30 Two studies used a similar
definition of POPF (prolonged discharge with an amylase concen-
tration at least three times more elevated in the fluid of drainage
compared with the serum level) on day 7 and 10,32,34 respectively.
Suc et al.33 considered a POPF as a 3-days consecutive discharge
with a fourfold increase in amylase. D’Andrea et al. considered
only radiologically-proven fistulae.31 A funnel plot showed no
obvious asymmetry (Supplementary material).
Description of the intervention
All the included studies compared fibrin sealants versus no inter-
vention. In addition to fibrin glue application, Carter et al.30 used
a falciform ligament patch sutured over the pancreatic stump. One
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Figure 1 Flow chart of the inclusion/exclusion process
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Table 1 Characteristics of the included studies
Country n Surgical procedure POPF definition Jadad score Comments
Intervention Control
D'Andrea
199431
Italy 43 54 PD (n = 70), LP (n = 23),
tumour excision (n = 4)
Radiological assessment 2
Suzuki 199534 Japan 26 30 LP >7-day long discharge of
an amylase-rich drain
fluid (threefold
elevation
above the level of
serum)
2
Suc 200333 France 102 80 PD (n = 141), LP (n = 41) 3 day-long discharge of
an amylase-rich drain
fluid (>fourfold elevation
above the level of
serum) and/or
radiological assessment
5 Compared to controls,
patients in the intervention
group received more
prophylactic sandostatin
analogues
Lillemoe 200432 USA 58 66 PD 10 days discharge of an
amylase-rich drain fluid
(>threefold elevation
above the level of
serum)
3 Soft glands only
Carter 201230 USA 50 51 LP ISGPF criteria 5 Soft glands only
Montorsi 201227 Italy 145 130 LP ISGPF criteria 2
Martin 201226 Australia 37 25 PD ISGPFcriteria 2 In the intervention group, all
anastomoses (pancreatico-
jejunostomy, choledoco-
jejunostom and entero-
enteral anastomosis) were
covered with fibrin sealant.
POPF, post-operative pancreatic fistula; PD, pancreaticoduodenectomy; LP, left pancreatectomy; ISGPF, International Study Group on Pancreatic Fistula.
Yes
7
6
5
4
3
2
1
Randomized? Double blind? Free of attrition? Adequate
random
sequence?
Adequate
blinding?
Allocation
concealement?
A priori
sample size
calculation?
No Unclear
Figure 2 Methodological appraisal
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trial applied fibrin glue inside the main pancreatic duct.33 In the
remaining studies, the fibrin sealant was applied on the pancrea-
ticojejunostomy or, in case of LP, on the suture or staple line of the
pancreatic stump. In the fibrin sealant group of the study by
Martin et al.,26 Tisseel® was applied to all anastomoses (not only
pancreaticojejunostomy) tailored during a PD. A part from one
study that assessed the role of a fibrin sealant patch,27 all trials
applied fibrin in a gelatinous form. The weighted mean ( stand-
ard deviation) price of fibrin sealant was $275 ( 128) per unit.
The various commercially available preparations used in the
included trials are presented in Table 2.
Effect of intervention
Primary outcome
The outputs of the meta-analysis are depicted in Fig. 3. Six trials
reported POPF incidence.27,30–34 Overall, regardless of group allo-
cation, 291 patients (35%) were diagnosed with a POPF. In PD
and LP, the pooled incidence rate of POPF was 20% (n = 67) and
45% (n = 224), respectively (Fig. 4). The highest rate was observed
in LP studies applying the ISGPF definition27,30 (52.6%, n = 198).
Compared with controls, patients receiving fibrin sealants had a
pooled OR of experiencing POPF of 0.83 (95% CI: 0.6–1.14),
P = 0.245, I2 = 0%, fixed effect model). In the two LP trials report-
ing the ISGPF-defined severity of a POPF,27,30 the effect of fibrin
sealants appeared to be more marked in the setting of severe POPF
[grade A: OR = 0.97 (95% CI: 0.61–1.55), P = 0.895, grade B: OR
= 0.84 (95% CI: 0.43–1.62), P = 0.597 and grade C: OR = 0.31
(95% CI: 0.06–1.52), P = 0.148, respectively].
Secondary outcomes
The incidence of overall complications was reported in four tri-
als,26,27,32,33 showing similar results in both groups (OR = 0.8 (95%
CI: 0.54–1.17), P = 0.249). There was borderline evidence sup-
porting that, compared with controls, patients treated with fibrin
sealants were 57% less likely to experience post-operative haem-
orrhage [OR = 0.43 (95% CI: 0.18–1.0), P = 0.05, NNT = 24]. A
statistical trend favouring fibrin sealants was observed when con-
sidering the incidence of intra-abdominal collection [OR = 0.52
(95% CI: 0.25–1.06), P = 0.073, NNT = 15]. There was no differ-
ence regarding acute pancreatitis (P = 0.828), invasive procedures
(P = 0.512), wound infection (P = 1) or death (P = 0.504) (see
Fig. 3). The length of hospital stay was not significantly shortened
after fibrin sealant use [WMD = –0.915 days (95% CI: -2.51 to
0.68), P = 0.262, I2 = 0%, fixed effect model]. No trials reported
thrombo-embolic events or allergic reactions.
Sensitivity and subgroup analyses
A subgroup analysis was performed in order to take the surgical
procedure (PD or LP) into account. There was no evidence of a
difference in the POPF incidence in either PD [OR = 1.05 (95%
CI: 0.61–1.8), P = 0.873] or LP [OR = 0.74 (95% CI: 0.5 -1.1), P =
0.140]. When analysing only trials with adequate methodology
(Jadad score3), the pooled OR was 0.97 (95% CI: 0.6–1.58), P =
0.896. After exclusion of trials not applying the ISGPF definition,
the pooled OR was 0.83 (95% CI: 0.53–1.29), P = 0.397. In a
sensitivity analysis of trials using a fibrin sealant preparation con-
taining aprotinin, the OR was 0.83 (95% CI: 0.52–1.32), P = 0.425.
No difference was observed after restricting the analysis to
patients described as having a soft pancreatic parenchyma (OR =
0.88 (95% CI: 0.48–1.63), P = 0.691). When analysing only trials
performing hand-sewn closure of the pancreatic remnant,31,34 the
OR was 0.29 (95% CI: 0.09–0.96), P = 0.042, random effect model.
Because trials assessing the role of fibrin sealants in PD had liberal
policies regarding pancreatico-digestive anastomosis (end-to-end
or end-to-side pancreaticojejunostomy, pancreaticogastrostomy,
pylorus-preservation or not, stent placement), neither sensitivity
nor subgroup analyses were feasible in this matter.
Discussion
The idea of applying topical fibrin as a means of improving local
haemostasis and enhancing wound healing was already reported
more than a century ago.35 Although there is abundant literature
assessing the role of fibrin sealants in surgical settings such as
orthopaedics,12 liver9,10 and cardiovascular14 surgery, their effec-
tiveness in pancreatic surgery remains scarce and inconclusive.
Table 2 Characteristics of fibrin sealant preparation used in the included studies
D'Andrea 199431 Suzuki 199534 Suc 200333 Lillemoe 200432 Carter 201230 Montorsi 201227 Martin 201226
Commercial name Unknown Tissucol/Tisseel® Tissucol/tisseel® Hemaseel APR® Vitagel® TachoSil® patch Tissucol/Tisseel®
Fibrinogen Human-derived
Unknown concentration
Human-derived
90 mg/ml
Human-derived
90 mg/ml
Human-derived
75–115 mg/ml
Autologous plasma Human-derived
5.5 mg/cm2
Human-derived
90 mg/ml
Factor XIII None 10–50 kIU/ml 10–50 kIU/ml None None None 10–50 kIU/ml
Thrombin Unknown origin Human-derived
500 IU/ml
Human-derived
500 IU/ml
Human derived
500 IU/ml
Bovine-derived
300 UI/ml
Human-derived
2 IU/cm2
Human-derived
500 IU/ml
Aprotinin Bovine-derived
5 000–20 000 kIU/ml
Bovine-derived
3 000 kIU/ml
Bovine-derived
30 000 kIU/ml
(added separately to
the preparation)
Bovine-derived
3000 kIU/ml
None None Bovine-derived
3000 kIU/ml
Price Unknown $160b $160b $164a $470a $395a $160b
aPrice as reported in the individual studies or bas estimated according to manufacturer product information. (http://www.ecomm.baxter.com). Currency conversion rates were calculated
on 20 December 2012 (www.ecomm.baxter.com/ecatalog)
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Figure 3 Forest plot depicting the results of the meta-analysis, fixed-effect model. The vertical line shows the null hypothesis (OR = 1). Odds
ratio (OR), post-operative pancreatic fistula (POPF), confidence interval (CI), nFS (number of patients in the fibrin sealant group), nC (number
of patients in the control group)
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Accordingly, this systematic review and meta-analysis was aimed
at gathering, analysing and critically appraising the best available
evidence on the effectiveness of fibrin sealant products at reducing
fistula formation after pancreatic resection.
Overall, one-third of the included patients experienced POPF,
consistent with the literature.36–38 A twofold higher risk of devel-
oping POPF was observed in patients undergoing LP (45%) com-
pared with PD (20%). This risk was even higher when the ISGPF
criteria were applied (52.6%), illustrating the fact that the ISGPF
identifies an important number of fistulae, including those with
little clinical relevance. The current study does not support the
routine clinical use of fibrin sealants in pancreatic surgery, as their
use is not associated with a significant reduction in POPF, overall
complications or length of hospital stay. In contrast, there was
some evidence for a markedly lower incidence (57%) of post-
operative bleeding events (OR = 0.43 95% CI: 0.18–1.0 P = 0.05)
after fibrin sealant use. This finding is in agreement with other
surgical studies reporting a reduced blood loss in patients receiv-
ing fibrin sealants.12,39–43 Besides technical failures such as non-
haemostatic suture lines or slipping ligatures, bleeding events after
pancreatic resection are usually related to vascular erosions caused
by a pancreatic leak.44 It could be argued that the lower risk of
haemorrhage in the fibrin sealant group constitutes a surrogate
marker of a decreased POPF rate. However, because only one
trial27 separately reported early and late complications, it was not
possible to perform a subgroup analysis focusing on delayed
bleeding events. Therefore, this assumption must be interpreted
with caution. The result of a 48% reduction in intra-abdominal
collections approached statistical significance (P = 0.073), repre-
senting weak evidence of the effectiveness of fibrin sealants on a
common complication after a pancreatic resection.
Aiming at distinguishing between overall and clinically relevant
fistula, a sensitivity analysis of trials grading the severity of the
observed fistula according to the ISGPF criteria27,30 was con-
ducted. Although not significant, it appeared that the magnitude
of effect attributed to the intervention increased along with the
severity of POPF, as patients receiving fibrin sealants experienced
a 3% (P = 0.895), 16% (P = 0. 597) and 69% (P = 0.148) lower risk
of POPF grade A, B, and C, respectively. Additionally, it could be
argued that among the fistulae reported as an overall incidence
rate and not graded according to severity,31–34 some must have
been truly clinically relevant. Because these could not be analysed
separately, the power of the sensitivity analysis was reduced.
Although statistical heterogeneity did not hamper the meta-
analyses reported herein, there was some degree of between-study
clinical variability. Several factors contributed to this. First, early
studies had various criteria for defining POPF, making them less
comparable in terms of POPF incidence rate. Hence, it was
decided to analyse separately the results of studies applying the
ISPGF definition, as well as performing a meta-analysis of the
ISGPF-defined severity of POPF. This strategy did not reveal a
significant difference in the POPF incidence nor interaction
caused by severity grade, consistent with the null hypothesis that
there is no effect of fibrin sealants on POPF. Second, one could
question the meaningfulness of pooling the results of studies held
in the settings of PD and LP in a unique meta-analysis. Thus,
subgroup analyses of patients undergoing either PD or LP were
performed. Both of these analyses were statistically insignificant.
Third, although all fibrin sealants used in the included studies are
mainly composed of fibrinogen and thrombin, their precise com-
position varies noticeably. For instance, aprotinin, which was used
in all but two trials, is an antiprotease molecule that could be
useful in preventing early degradation of fibrinogen by pancreatic
proteolytic enzymes. However, performing sensitivity analyses of
fibrin sealants with and without aprotinin did not affect the
results.
897 patients
Exclusion of patients
undergoing neither
pancreaticoduodenectomy
nor left pancreatectomy (n = 4)
Exclusion of one trial26
from the analysis regarding
POPF (only overall morbidity
reported) ( n = 62)
pancreaticoduodenectomy
Fibrin sealant group: 207
Control group: 190
291 (35%) patients
experienced POPF
Left pancreatectomy
Fibrin sealant group: 253
Control group: 243
Patients with POPF
Fibrin sealant group: 34
Control group: 33
Patients with POPF
Fibrin sealant group: 109
Control group: 115
Figure 4 Diagram of the incidence of a post-operative pancreatic fistula (POPF)
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Looking at the potential confounding introduced by variability
in the surgical technique, a sensitivity analysis was performed,
retaining only those procedures31,34 where the pancreatic stump
was hand-sewn. This analysis revealed a statistically significant
71% lower risk of a POPF for patients receiving fibrin sealants
compared with controls, suggesting that fibrin sealants could be
more beneficial in the setting of manual closure of the transected
parenchyma. Notwithstanding the surgical technique, the trials by
D’Andrea et al.31 and Suzuki et al.34 were also of low methodologi-
cal quality, limiting the generalizability of this finding.
The trials included herein were of heterogenous quality. Two
trials had a high Jadad score,30,33 but two others used a question-
able random sequence generation method (flip a coin,26 or
drawing of lots34). Only one trial reported adequate allocation
concealment,30 and blinding of outcomes assessors was described
in three studies.30,32,33 Thus, the risk of observer bias was high,
considering the fact that surgeons might have been biased by their
awareness of allocation in their diagnosis of POPF. In addition,
selection bias was likely in several situations, owing to the exclu-
sion of patients after randomization30 and the presence of signifi-
cant baseline imbalance in gender,27 or others acknowledged
confounding factors such as prophylactic somatostatin analogues
administration.33 Again, restricting the analyses to trials with a
more rigorous design revealed no interaction.
Fibrin sealants are expensive devices. On the basis of a weighted
mean price of $275 per application, and assuming the use of a
single unit per patient, $6600 (NNT = 24) and $4125 (NNT = 15)
would be necessary to prevent one patient from experiencing
post-operative bleeding and intra-abdominal collection(s),
respectively. Of note, these observations rely on the assumption
that the use of fibrin sealant is truly associated with a lower risk of
bleeding events and intra-abdominal collections. This remains a
matter debate, and further studies are warranted.
This is the first meta-analysis evaluating the role of fibrin seal-
ants in pancreatic surgery. The current findings do not provide the
evidence to justify routine clinical use of costly interventions such
as fibrin sealants in an era of scarce resources, and should lead to
further research in the form of additional adequately powered
prospective randomized trials.
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Figure S1 Funnel plot, post-operative pancreatic fistula data. Odds ratio
(OR). Each point illustrates a trial. The solid line depicts the effect size (pooled
OR = 0.82). Studies located on the left side of the null hypothesis (Log OR =
0) support the intervention. Asymmetry may suggest publication bias.
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